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OBJECTIVES The goal of this study was to determine the prevalence of worsening renal function (WRF)
among hospitalized heart failure (HF) patients, clinical predictors of WRF, and hospital
outcomes associated with WRF.
BACKGROUND Impaired renal function is associated with poor outcomes among chronic HF patients.
METHODS Chart reviews were performed on 1,004 consecutive patients admitted for a primary diagnosis
of HF from 11 geographically diverse hospitals. Cox regression model analysis was used to
identify independent predictors for WRF, defined as a rise in serum creatinine of0.3 mg/dl
(26.5 mol/l). Bivariate analysis was used to determine associations of development of WRF
with outcomes (in-hospital death, in-hospital complications, and length of stay).
RESULTS Among 1,004 HF patients studied, WRF developed in 27%. In the majority of cases, WRF
occurred within three days of admission. History of HF or diabetes mellitus, admission
creatinine 1.5 mg/dl (132.6 mol/l), and systolic blood pressure 160 mm Hg were
independently associated with higher risk of WRF. A point score based on these character-
istics and their relative risk ratios predicted those at risk for WRF. Hospital deaths (adjusted
risk ratio [ARR] 7.5; 95% confidence intervals [CI] 2.9, 19.3), complications (ARR 2.1; CI
1.5, 3.0), and length of hospitalizations 10 days (ARR 3.2, CI 2.2, 4.9) were greater among
patients with WRF.
CONCLUSIONS Worsening renal function occurs frequently among hospitalized HF patients and is associated
with significantly worse outcomes. Clinical characteristics available at hospital admission can
be used to identify patients at increased risk for developing WRF. (J Am Coll Cardiol 2004;
43:61–7) © 2004 by the American College of Cardiology Foundation
Several studies of patients with heart failure (HF) have
reported an association between impaired renal function and
unfavorable outcomes (1–8). The change in renal function
during hospitalization for HF may also have prognostic
importance. Krumholz et al. (9), in a study of Medicare
beneficiaries with HF, demonstrated that worsened renal
function (WRF), defined as a rise in serum creatinine of
0.3 mg/dl (26.5 mol/l) during hospitalization, occurred
frequently (28% incidence) and was associated with specific
clinical characteristics present upon admission. In addition,
patients with WRF had longer lengths of stay, higher
in-hospital costs, increased in-hospital mortality, and
greater likelihood of readmission. However, that study
included only Medicare patients and needs to be validated in
a general HF population. Therefore, we designed a multi-
center investigation to determine the frequency and timing,
as well as the predictors, of WRF among a broad population
of patients with HF. We also sought to identify those at
greatest risk for developing WRF during their hospitaliza-
tions based on admission clinical characteristics.
METHODS
Data source. We obtained inpatient medical records for a
geographically diverse sample of HF patients hospitalized
between July 1, 1997, and June 30, 1998, at 11 academic
medical centers. The participating sites were Rhode Island
Hospital, Yale-New Haven Hospital, Duke University
Medical Center, Hospital of the University of Pennsylvania,
University of Cincinnati Medical Center, Brigham and
Women’s Hospital, University Health Center-University of
Maryland, San Francisco Veterans Affairs Medical Center,
From the *Section of Cardiology, Boston Medical Center, Boston, Massachusetts;
†Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nash-
ville, Tennessee; ‡Section of Cardiovascular Medicine, and §Section of Health Policy
and Administration, Department of Epidemiology and Public Health, Yale Univer-
sity School of Medicine, New Haven, Connecticut; Ohio State University Division
of Cardiology, Columbus, Ohio; ¶Duke University Medical Center, Durham, North
Carolina; #Division of Cardiology, University of Maryland, Baltimore, Maryland;
**University of Pennsylvania, Philadelphia, Pennsylvania; ††Department of Medicine,
University of California, San Francisco, California; ‡‡Department of Veterans Affairs
Medical Center, San Francisco, California; §§Cardiovascular Division, Washington
University School of Medicine, St. Louis, Missouri; Cardiovascular Division,
Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School,
Boston, Massachusetts; ¶¶Department of Cardiology, The Cleveland Clinic Foun-
dation, Cleveland, Ohio; ***Qualidigm, Middletown, Connecticut; and the †††Yale-
New Haven Hospital Center for Outcomes Research and Evaluation, New Haven,
Connecticut. Supported by Biogen, Inc., Cambridge, Massachusetts. Dr. Loh is
currently at Wyeth-Ayerst Research, Radnor, Pennsylvania.
Manuscript received January 17, 2003; revised manuscript received July 16, 2003,
accepted July 22, 2003.
Journal of the American College of Cardiology Vol. 43, No. 1, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.07.031
Barnes Jewish Hospital, Vanderbilt University Medical
Center, and The Cleveland Clinic Foundation. Consecutive
HF hospitalizations were identified using International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) principal discharge diagnoses codes
428.0, 428.1, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11,
404.13, 404.91, and 404.93.
Four nurses experienced in critical care or emergency care
and affiliated with an independent contract research orga-
nization abstracted data from medical records. To verify the
accuracy of chart abstraction, an independent nurse abstrac-
tor re-evaluated information in four categories (creatinine,
inclusion and exclusion criteria, and discharge dates) in 55
charts (15 charts for each of three abstractors and 10 for the
fourth). Discrepancies between the original abstractions and
these reassessments were 0.4% and were all corrected.
Creatinine values for all 1,004 patients in the final study
population were checked, and no discrepancies were de-
tected. In addition, comprehensive examinations of all data
fields were completed in a subset of 10% of the subjects.
Less than 0.5% discrepancy was detected.
The abstractors confirmed the diagnosis of HF in this
group by documenting at least one symptom and at least one
sign of HF. Symptoms included new onset or worsening
shortness of breath (dyspnea at rest or with exertion,
orthopnea, paroxysmal nocturnal dyspnea, cough/nocturnal
cough) or nonspecific symptoms that may be manifestations
of HF (fatigue, confusion/disorientation). Signs included
increased jugular venous pressure, S3 gallop, bilateral pul-
monary rales or crackles (more than basilar), hypotension/
cardiogenic shock, cardiac arrest, respiratory rate 24,
peripheral edema, increased weight from baseline, or radio-
logic signs (pulmonary edema, cephalization of pulmonary
vessels, pleural fluid, interstitial edema, alveolar fluid/
edema, or cardiomegaly).
Exclusion criteria were designed to assemble a population
of typical adult HF patients. Patients were excluded if their
hospitalizations were for an elective procedure (e.g., percu-
taneous transluminal coronary angioplasty, pacemaker, or
cardioversion) or if their hospital length of stay was 2
days. Other exclusion criteria included severe aortic stenosis,
anticipated cardiac transplantation, transfer from another
in-hospital setting, chronic dialysis, use of a left ventricular
(LV) assist device, high-output HF, age 20 years, con-
comitant use of an investigational product or device, and
patients receiving chemotherapy. Subjects were also ex-
cluded if creatinine values were not documented at admis-
sion.
Outcomes and candidate predictors associated with WRF.
The principal outcome was WRF, defined as an increase in
serum creatinine of 0.3 mg/dl (26.5 mol/l) from admis-
sion, consistent with several previous investigations (9–11).
Baseline clinical variables included subjects’ demographic
characteristics, past medical histories, medications on ad-
mission, and symptoms and physical signs on presentation.
In analyses to determine the prognostic importance of
WRF, the outcome measures were hospital length of stay,
in-hospital mortality, and complications occurring after the
rise in creatinine. Complications were defined as shock,
myocardial infarction, stroke, major infection/sepsis, clini-
cally significant hypotension, and new onset atrial fibrilla-
tion (AF) with ventricular rates 100 beats/min.
Statistical analysis. Chi-square analyses were used to com-
pare incidence of WRF between different recruitment sites.
A Kaplan-Meier plot of freedom from WRF was con-
structed to show the process of WRF development. In
bivariate analyses, the associations between patients’ char-
acteristics and the development of WRF were assessed.
Independent predictors of WRF were identified using
multivariable Cox regression models with stepwise selection
method. Time to WRF was the outcome with censoring at
the time of hospital discharge for those without an increase
in creatinine. Variables were entered at an entry level of
significance p  0.1 and kept in the model at an exit
significance level p  0.05. To confirm that our model is
stable, we used bootstrap analysis method (12). We boot-
strapped the original data 1,000 times to get 1,000 samples;
each bootstrapping sample was the same size, each was
randomly selected from the original data, and each was
selected independently, that is, with the chance that records
could be selected more than once. For each bootstrapping
sample, we repeated our model and determined the coeffi-
cients. We could, thereby, generate summary analysis for
the 1,000 models and determine variation of the coefficients.
By showing only a small variation of coefficients, we
concluded that the model was stable. A risk score was
calculated as the arithmetic sum of point values assigned to
each independent predictor based on the multivariate-
adjusted risk relationship in the final Cox model, that is,
proportionate to the hazard ratio. The relationship between
this risk score and WRF was evaluated using the Cochran-
Armitage (13) trend test to assess significance of the trend.
Associations of the development of WRF with patients’
outcomes (length of stay 10 days, complications, and
in-hospital mortality) were assessed through bivariate anal-
ysis. The analysis was repeated on subgroups stratified by
age (20 to 59 years, 60 to 79 years, 80 years), gender, and
baseline creatinine (creatinine 1.0 mg/dl [88.4 mol/l],
1.0 [88.4 mol/l]  creatinine 1.5 mg/dl [132.6 mol/l],
1.5 mg/dl [132.6 mol/l]  creatinine 2.5 mg/dl [221.0
mol/l]; creatinine 2.5 mg/dl [221.0 mol/l]). The asso-
ciation of WRF with patients’ outcomes was assessed by
Abbreviations and Acronyms
AF  atrial fibrillation
BP  blood pressure
BUN  blood urea nitrogen
EF  ejection fraction
HF  heart failure
LV  left ventricular
WRF  worsening renal function
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logistic regression analysis adjusting for potential confound-
ing factors, such as: significant predictors of WRF, as well as
age, race, history of AF, cerebral vascular accident, HF,
diabetes mellitus, previous use of digoxin, symptoms of
othopnea, presentation of hypotension (i.e., blood pressure
[BP] 90 mm Hg with associated symptoms), edema, high
respiratory rate, systolic BP more than 160 mm Hg,
laboratory values of potassium, creatinine, and blood urea
nitrogen (BUN). Odds ratios and their 95% confidence
intervals were transferred into risk ratios, and the corre-
sponding confidence intervals (14).
Variables missing from more than 15% of the study popu-
lation were excluded from consideration. These variables were
oxygen saturation (30%), gamma-glutamyltranspeptidase
(94%), aspartate aminotransferase (36%), alanine amino-
transferase (64%), and bilirubin (48%). Continuous vari-
ables, dichotomized or categorized based on clinical signif-
icance as shown in the tables, were age, systolic BP, pulse,
respiratory rate, sodium, potassium, creatinine, BUN, and
hematocrit. Missing categorical data elements were assumed
to be “not present” for the variable, and a separate dummy
indicator was used if more than 5% of the values were
missing, as was the case for smoking status (8%) and LV
ejection fraction (EF) (10.5%).
The study was funded by Biogen, Inc., Cambridge,
Massachusetts; decisions regarding the study design, collec-
tion, analysis, and interpretation of the data, and the
approval of the finished manuscript for publication were at
the full discretion of the authors. All analyses were per-
formed using PC-SAS version 8.0 (SAS Institute, Inc.,
Cary, North Carolina) and STATA version 6.0 (Stata
Corp., College Station, Texas).
RESULTS
Study population. Charts from 1,009 patients were ab-
stracted. Five of these charts were excluded from analysis
because they were missing admission creatinine levels. The
remaining 1,004 patients constituted our study sample.
Patient characteristics. Patient baseline characteristics are
listed in Table 1. Mean age (SD) of the study population
was 67 15 years with 18% of the cohort80 years of age.
Nearly half the total population was female, and 54% were
white. Mean EF was 34.2% among the 899 of 1,004
subjects (89.5%) whose EFs were measured. Left ventricular
EF values measured 55% among 21% of the subjects
whose EFs were measured.
Admission symptoms and signs are listed in Table 2. At
presentation, most of the study population complained of
dyspnea, and two-thirds had peripheral edema. The preva-
lence of baseline severe renal insufficiency was relatively low
(baseline creatinine 2.5 mg/dl [221.0 mol/l] in 11% and
4.0 mg/dl [353.6 mol/l] in 3% of the subjects).
Incidence of WRF. Worsening renal function occurred in
273 patients (27%) (Fig. 1). The incidence of WRF was
similar across the 11 recruitment sites, and its onset oc-
curred within the first three hospital days in 142 of the 273
patients (52%).
Risk factor stratification based on medical history and
hospital presentation. Table 3 indicates independent risk
factors for WRF. A history of HF, pharmacologically
treated diabetes mellitus, admission creatinine, and elevated
systolic BP (160 mm Hg) were the factors most strongly
associated with WRF. In addition, admission creatinine
(1.5 mg/dl [132.6 mol/l]) 2.5 mg/dl (221 mol/l) as
well as 2.5 mg/dl (221.0 mol/l) were associated with
incremental risk compared with admission creatinine 1.5
mg/dl (132.6 mol/l). The bias of coefficients of these
factors is negligible (rounds to 0), and bootstrap analysis
with 1,000 replicas demonstrates that the model is stable.
A risk score for WRF was devised based on the risk
factors. Points were assigned to each risk factor listed in
Table 3 based on the respective relative risk ratios. One
point was assigned to history of HF, history of diabetes
mellitus, and systolic BP 160 mm Hg at admission. Two
points were assigned to creatinine 1.5 (132.6 mol/l) to 2.4
mg/dl (212.16 mol/l), and three points were assigned to
creatinine 2.5 mg/dl (221 mol/l). Table 4 shows the
relationship between risk score and WRF. Patients with
higher point totals were more likely to develop WRF. The
22% of the total sample with a risk score of 4 had a 53%
likelihood of developing WRF compared with only a 10%
risk among the 12% of the population with a risk score of 0
(p  0.001 for the trend). Relative to the group of patients
with a risk score of 0, both the groups of patients with scores
1 and 2 had approximately twice the likelihood of develop-
ing WRF (see “relative risk” column in Table 4). Compared
with those with risk score of 0, the group with risk score 3
had approximately triple the risk of developing WRF. The
group with risk score 4 had 5 times the risk.
WRF and outcomes. Logistic regression analysis shows
that clinical outcomes were significantly worse among sub-
jects with WRF. Risk ratios for death during hospitaliza-
tion, complications, and length of stay 10 days increased
sevenfold, twofold, and threefold, respectively, in compari-
sons of those who developed WRF with those who did not.
After adjusting for potential confounding factors including
demographics (age, race), medical history (AF, cerebrovas-
cular accident, HF, diabetes, use of digoxin), admission
characteristics (othopnea, hypotension, edema, high respi-
ratory rate, systolic BP more than 160 mm Hg), and lab
values (potassium, creatinine, and BUN), associations be-
tween WRF and worse clinical outcomes remained signif-
icant. Results were consistent among subgroups defined by
strata of age, gender, and baseline creatinine.
DISCUSSION
The present study adds to the growing evidence that WRF
is common among patients hospitalized for HF and is
associated with markedly poorer outcomes. The principal
findings are: 1) 27% of patients develop WRF, as defined by
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serum creatinine increase 0.3 mg/dl (26.5 mol/l), a
previously identified threshold associated with worse out-
comes; 2) several baseline characteristics are associated with
the development of WRF, and a score derived by weighting
these variables is highly predictive; and 3) in a diverse group
of consecutive patients, WRF remains a powerful predictor
of increased risk of death, increased complications, and
prolonged hospitalizations.
The risk associated with post-admission WRF was first
reported in a study limited to older HF patients (mean age
79 8 years; 44% age over 80 years) that showed a similarly
high incidence of WRF (28%) (9). Both the previous and
the present studies demonstrate that WRF occurs early,
appearing within seven days of hospitalization in 90% of
cases and 81% of cases, respectively (data not shown). The
early occurrence of WRF in the course of hospitalizations
for decompensated HF suggests that renal deterioration is
related to inherent mechanisms of disease or to the impact
of therapy administered upon admission, rather than to
progressively worsening clinical status over prolonged hos-
pitalization.
The mechanisms responsible for WRF are complex and
not well-defined. Intuitively, hemodynamic abnormalities,
such as hypotension or low cardiac output, might be
expected to play a role (15). However, hypotension was
uncommon in this population, and, in fact, it was hyper-
tension that emerged as a predictor of WRF. Similarly,
intravascular hypovolemia can cause WRF, but our data
indicated that WRF was more likely in patients with
elevated jugular venous pressure at admission. Still, corrob-
orating hemodynamic measurements were rarely available.
It is noteworthy that EF was not a predictor of WRF and
that, among patient subgroups with mild, moderate, and
severe LV systolic impairment as well as those with normal
Table 1. Baseline Characteristics of Heart Failure Patients and WRF
WRF
p Value
Total (1,004) No (731) Yes (273)
# % # % # %
Demographics
Age: mean (SD) 67.3 14.6 66.8 15.0 68.7 13.4 0.07
Age 80 182 18.1 133 18.2 49 17.9 0.93
Female 490 48.8 359 49.1 131 48.0 0.75
White 538 53.6 390 53.4 148 54.2 0.81
Smoker 235 23.4 178 24.4 57 20.9 0.25
Ejection fraction 0.33
Normal (LVEF 55) 212 21.1 154 21.1 58 21.2 0.95
Mild LV dysfunction (55  LVEF  40) 164 16.3 114 15.6 50 18.3 0.30
Moderate LV dysfunction (40  LVEF  20) 392 39.0 279 38.2 113 41.4 0.35
Severe LV dysfunction (20  LVEF  0) 131 13.0 102 14.0 29 10.6 0.16
Missing assessment of LVEF 105 10.5 82 11.2 23 8.4 0.20
Medical history
Prior heart failure 636 63.3 444 60.7 192 70.3 0.0050*
Prior renal failure 230 22.9 120 16.4 110 40.3 0.0001*
Hypertension 703 70.0 503 68.8 200 73.3 0.17
Atrial fibrillation 237 23.6 170 23.3 67 24.5 0.67
Noninsulin-dependent diabetes 206 20.5 139 19.0 67 24.5 0.05
Insulin-dependent diabetes 204 20.3 133 18.2 71 26.0 0.0062*
Stroke 155 15.4 98 13.4 57 20.9 0.0035*
Peripheral vascular diesease 128 12.7 80 10.9 48 17.6 0.0050*
Angina 360 35.9 252 34.5 108 39.6 0.14
Myocardial infarction 302 30.1 213 29.1 89 32.6 0.29
Prior medications
Prior ACE-I 473 47.1 335 45.8 138 50.5 0.18
Prior ARBs 52 5.2 39 5.3 13 4.8 0.72
Prior BB 224 22.3 154 21.1 70 25.6 0.12
Prior CCB 258 25.7 166 22.7 92 33.7 0.0004
Prior vasodilators 337 33.6 226 30.9 111 40.7 0.0036*
Nitrates 287 28.6 191 26.1 96 35.2 0.0048*
Hydralazine 48 4.8 26 3.6 22 8.1 0.0029*
Others 57 5.7 39 5.3 18 6.6 0.44
Prior diuretics 703 70.0 508 69.5 195 71.4 0.55
Prior ASA 230 22.9 153 20.9 77 28.2 0.0147*
Prior NSAID 63 6.3 49 6.7 14 5.1 0.36
Prior digoxin 371 37.0 278 38.0 93 34.1 0.25
*p  0.05.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; ASA  aspirin; BB  beta-blocker; CCB  calcium channel blocker; LV  left
ventricular; LVEF  left ventricular ejection fraction; NSAID  nonsteroidal anti-inflammatory drug; WRF  worsening renal function.
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LVEFs, proportions of patients who developed WRF were
similar. These findings are consistent with those of Wein-
feld et al. (16) who showed no correlation between renal
deterioration and cardiac output, filling pressures, or base-
line systemic vascular resistance in a study of 48 HF
patients. It seems likely that other endogenous vascular
factors, including endothelin, nitric oxide, prostaglandin,
natriuretic peptides, and vasopeptidase inhibitors may affect
renal perfusion independently of central hemodynamics
(17,18). Comorbid conditions or the treatments utilized
may also play a critical role in the development of WRF.
In addition, although HF patients with elevated creati-
nine levels at hospital admission were especially likely to
develop WRF, it was remarkable that increases in creatinine
0.3 mg/dl (26.5 mol/l) were clinically consequential in
all subgroups of subjects, regardless of baseline or peak
Table 2. Presenting Symptoms and Signs of Heart Failure Patients and WRF
WRF
p Value
Total (1,004) No (731) Yes (273)
# % # % # %
Symptoms upon hospitalization for heart failure
Dypnea at rest or on exertion 960 95.6 696 95.2 264 96.7 0.30
Othopnea 592 59.0 428 58.5 164 60.1 0.66
Paroxysmal nocturnal dyspnea 399 39.7 287 39.3 112 41.0 0.61
Fatigue 257 25.6 201 27.5 56 20.5 0.0241*
Confusion/disorientation 52 5.2 41 5.6 11 4.0 0.32
Signs on presentation
S3 gallop 263 26.2 185 25.3 78 28.6 0.30
Increased jugular venous pressure 543 54.1 376 51.4 167 61.2 0.0059*
Bilateral rales or crackles  basilar 456 45.4 325 44.5 131 48.0 0.32
Peripheral edema 694 69.1 504 68.9 190 69.6 0.84
Hypotension (SBP 90, with symptoms) 25 2.5 17 2.3 8 2.9 0.58
Hypertension (SBP 160) 322 32.1 217 29.7 105 38.5 0.0080*
Pulse 100 beats/min 383 38.1 292 39.9 91 33.3 0.06
Respiratory rate 24 beats/min 499 49.7 351 48.0 148 54.2 0.08
Atrial fibillation 190 18.9 145 19.8 45 16.5 0.23
CHF/pulmonary edema on CXR 773 77.0 555 75.9 218 79.9 0.19
Laboratory results
Sodium 145 23 2.3 14 1.9 9 3.3 0.19
Sodium 135 142 14.1 104 14.2 38 13.9 0.90
Potassium 5 96 9.6 62 8.5 34 12.5 0.06
1.5  creatinine 2.5 247 24.6 155 21.2 92 33.7 0.0001*
Creatinine 2.5 112 11.2 50 6.8 62 22.7 0.0001*
BUN 50 116 11.6 63 8.6 53 19.4 0.0001*
Hematocrit 30 128 12.7 83 11.4 45 16.5 0.0301*
BUN  blood urea nitrogen; CHF  congestive heart failure; CXR  chest X-ray; SBP  systolic blood pressure; WRF  worsening renal function.
Figure 1. Time without worsening renal function during heart failure hospitalizations. WRF  worsening renal function.
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serum creatinine level. In fact, when change in creatinine is
expressed as a percentage, the 0.3 mg/dl increase among
those with high baseline serum creatinine was relatively
smaller than the percent creatinine change among those
with low baseline serum creatinine, and yet all manifest
similar untoward outcomes.
Multivariable analysis identified four clinical parameters
present at admission (history of pre-existing HF, diabetes
mellitus, admission creatinine of 1.5 mg/dl [132.6 mol/
l], admission systolic BP 160 mm Hg) that are strongly
and independently associated with WRF. Notably, age was
not associated with WRF in this study population, indicat-
ing that age-related systemic effects are not specifically
related to the onset of WRF. A simple score based on these
admission variables distinguished risks of developing WRF
ranging from 10% to 53% among different HF patients.
Although it is recognized that renal function may be
more accurately assessed using calculated creatinine clear-
ance, it is also relevant that 24-h urine collection is more
cumbersome and costly and lends itself less readily to serial
measurement. A strength of this investigation is that the
simpler and more readily available measurement of serum
creatinine provides a powerful tool for predicting adverse
outcomes. The previous report by Weinfeld et al. (16)
studying renal function and HF highlights these method-
ological differences. Those investigators used creatinine
clearance rates as well as serum creatinine to assess renal
performance among HF patients. Patients with reduced
creatinine clearance rates were more likely to develop
aggravated renal deterioration and poor outcomes despite
similar baseline creatinine level. Nonetheless, our study
provides firm support for using increases in serum creatinine
to predict adverse outcomes regardless of “actual” renal
function. Furthermore, serum creatinine levels are less
expensive than assessments of creatinine clearance, and they
are more clinically useful for monitoring short-term fluctu-
ations in renal function.
Whether 0.3 mg/dl (26.5 mol/l) increases in serum
creatinine is the best gradation of renal deterioration is also
controversial. Some investigators have used a rise in serum
creatinine above a threshold to define renal insufficiency
(e.g., creatinine2.5 mg/dl [221.0 mol/l]) or a percentage
increase from baseline (e.g., 25% increase), or a combina-
tion of these factors (15). In the current investigation, we
utilized a predetermined definition of an increase in creat-
inine 0.3 mg/dl from admission based on observations in
prior studies (9–11). Notably, this definition of WRF
enables us to show that WRF is associated with adverse
outcomes even in subjects whose peak serum creatinine was
2.5 mg/dl (221.0 mol/l). Other definitions of WRF are
compared in a related analysis by Gottlieb et al. (19) who
demonstrate that any detectable change in serum creatinine,
regardless of peak creatinine, is associated with increased
mortality and prolonged hospital stay. Using a threshold of
0.3 mg/dl creatinine, the sensitivity and specificity of WRF
were 81% and 62%, respectively, for in-hospital death and
64% and 65% for length of hospitalization 10 days.
Although WRF was clearly associated with poor in-
hospital outcomes, it is not clear whether it is a marker of
risk or a cause. Nonetheless, it is plausible that interventions
that prevent creatinine increases during HF hospitalizations
may improve outcomes. Whatever the relationship between
creatinine and HF pathophysiology, the possibility that such
small increases in creatinine can sensitively predict worse
outcomes provides key opportunities to identify patients at
risk.
Study limitations. This analysis did not investigate the
impact of in-hospital management choices on the risk of
WRF. Choices of medications (as well as their timing and
doses), concomitant disease, and procedures are all impor-
tant considerations in assessing changes in renal perfor-
mance. We were also limited in this retrospective analysis by
information that was available in the chart. To improve the
specificity of the information, we made use of various
Table 3. Risk Factors for WRF*
Description
Parameter
Estimate
Hazard
Ratio
Confidence Interval†
Weight
Bootstrap Results‡ (1,000 Replicas)
Lower Upper Bias Lower Upper
History of prior CHF 0.2715 1.312 1.008 1.707 1 0.0048 0.0061 0.5368
Diabetes 0.3375 1.401 1.102 1.783 1 0.0022 0.1007 0.5744
SBP 160 0.3108 1.365 1.064 1.749 1 0.0004 0.0624 0.5592
1.5  creatinine  2.5 0.7408 2.098 1.595 2.760 2 0.0029 0.4914 0.9903
Creatinine 2.5 1.2448 3.472 2.537 4.752 3 0.0047 0.9315 1.5581
*Cox regression with stepwise method using baseline as candidate variables; †95% confidence interval of hazard ratio; ‡ Only bias from the original parameter estimate and 95%
confidence interval of the original parameter estimates were reported.
CHF  congestive heart failure; SBP  systolic blood pressure; WRF  worsening renal failure.
Table 4. Risk Score and WRF
Score # %
WRF
# %
Relative
Risk
0 123 12.25 12 9.76 1 (Reference)
1 257 25.60 48 18.68 1.91
2 251 25.00 51 20.32 2.08
3 155 15.44 47 30.32 3.11
4 218 21.71 115 52.75 5.40
Cochran-Armiage
trend test (p value)
0.001
Total 1,004 100 273 27.19
Score for “1.5  creatinine 2.5” is 2 and for “creatinine 2.5” is 3.
WRF  worsening renal function.
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sources, when possible. For example, diabetes was coded
only when patients were receiving medications (parenteral
or oral) for this condition.
Conclusions. This large and diverse cohort study demon-
strates that WRF occurs frequently in hospitalized HF
patients and is associated with adverse outcomes. This
association remains strong in younger as well as older
patients. Significant predictors of in-hospital renal dysfunc-
tion include elevated baseline serum creatinine, a history of
HF or diabetes, and elevated systolic BP. Relatively small
rises in serum creatinine (0.3 mg/dl [26.5 mol/l]) have
adverse prognostic significance, irrespective of the patient’s
baseline renal function or peak serum creatinine. Surpris-
ingly, we found no clear relationship between hypotension
or the severity of LV systolic dysfunction and the occurrence
of WRF. Additional research is required to better delineate
in-hospital factors that may precipitate WRF. Furthermore,
it will be important to determine whether WRF is itself the
cause of increased morbidity and mortality in these patients
and, therefore, a potential target for intervention, or if WRF
is simply a marker of patients with more severe pathophys-
iologic derangements.
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